Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Abiad Visits the Karantina Warehouse and Public Hospital with a Delegation from the Republic of Korea and UNICEF

 
Following the announcement of new contribution from the Republic of Korea to ensure new-borns’ lifesaving care across selected governmental hospitals and the availability of essential paediatric acute medications in primary healthcare centres, the minister of public health held a joint field visit to the Karantina warehouse and hospital with Korean Ambassador to Lebanon and UNICEF Representative. 

The new funding will ensure the access of vulnerable populations to essential medications at primary healthcare centres and intensive lifesaving care services in public hospitals to avoid any supply rupture and allow timely access to acute treatments for children and mothers.  

The Minister of Public Health, Dr. Firass Abiad, indicated that "this donation will contribute to supporting the most vulnerable". He pointed out that "this is not the first time that the Republic of Korea  and UNICEF have stood by Lebanon.  through cooperation with partners, the Ministry of Public Health, in light of the difficult economic and political circumstances in Lebanon and the fact that Lebanon is hosting large numbers of displaced people, is trying to fulfill its duties towards everyone by providing health services and medicine in Primary health care centers".

Ambassador of the Republic of Korea in Lebanon, Mr.  Il Park said: “Korea recognizes the importance of providing essential healthcare services to the most vulnerable members of society, particularly children and newborns. We firmly believe that every child deserves the right to receive proper medical attention and care, regardless of their circumstances.”

The procured acute medications includes antibiotics, and anti-inflammatories allow to fill the gap in the acute medication supply induced by high demand for care from the most vulnerable children in Lebanon. Supporting vulnerable families to cover the out of pocket payment for their infants and children intensive care services helps eliminate the financial barrier to accessing lifesaving care. 

Edouard Beigbeder, UNICEF Representative in Lebanon, emphasized the organization's dedication to bridging vital healthcare access disparities and maintaining life-saving assistance for mothers and children in Lebanon. “Thanks to the ongoing generous support from the Republic of Korea, we can broaden our initiatives to encompass more vulnerable areas and additional hospitals, with a particular focus on enhancing support in Baalbek and Akkar."
    ...
    22
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DC04 CECLOR B Cefaclor (monohydrate) - 250mg/5ml 250mg/5ml Granules for suspension 851,100 L.L
J07BK01 VARIVAX B Varicella virus, live attenuated - 1350PFU Injectable powder for suspension+diluent 4,102,751 L.L
R01AB06 TRIOFAN B Xylometazoline HCl - 0.5mg/ml, Carbocysteine - 5mg/ml Spray, solution 608,761 L.L
B03AD04 MALTOFER B Iron trivalent (hydroxide polymaltose) - 10mg/ml 50mg/5ml Syrup 589,947 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 40mg 40mg Tablet, film coated 1,032,071 L.L
C10AB04 LOPID B Gemfibrozil - 600mg 600mg Tablet, film coated 498,566 L.L
R01AB06 TRIOFAN B Xylometazoline HCl - 1mg/ml, Carbocysteine - 10mg/ml Spray, solution 646,388 L.L
B03AD04 MALTOFER B Iron trivalent (hydroxide polymaltose) - 50mg/ml 50mg/ml Drops solution 649,076 L.L
C09CA08 VOTUM B Olmesartan medoxomil - 40mg 40mg Tablet, film coated 1,032,071 L.L
J01DC04 CECLOR MR B Cefaclor (monohydrate) - 500mg 500mg Tablet, film coated, modified release 1,226,096 L.L
L01EH01 TYKERB B Lapatinib ditosylate - 250mg 250mg Tablet, film coated 101,971,611 L.L
R06AE07 ZYRTEC B Cetirizine (dihydrochloride) - 1% 1% Drops 170,668 L.L
B03AD04 MALTOFER B Iron trivalent (hydroxide polymaltose) - 50mg/ml 50mg/ml Drops solution 649,076 L.L
G04CA04 SILOSIN B Silodosine - 4mg 4mg Capsule 1,251,693 L.L
J01DC04 CECLOR MR B Cefaclor (monohydrate) - 750mg 750mg Tablet, film coated, modified release 1,555,018 L.L
J07BM03 GARDASIL 9 HUMAN PAPILLOMAVIRUS 9- VALENT VACCINE RECOMBINANT B Papillomavirus (human type 6) - 30mcg/0.5ml, Papillomavirus (human type 11) - 40mcg/0.5ml, Papillomavirus (human type 16) - 60mcg/0.5ml, Papillomavirus (human type 18) - 40mcg/0.5ml, Papillomavirus (human type 31) - 20mcg/0.5ml, Papillomavirus (human type 33) - 20mcg/0.5ml, Papillomavirus (human type 45) - 20mcg/0.5ml, Papillomavirus (human type 52) - 20mcg/0.5ml, Papillomavirus (human type 58) - 20mcg/0.5ml Injectable suspension 14,139,396 L.L
L01EJ01 JAKAVI B Ruxolitinib - 5mg 5mg Tablet 172,845,338 L.L
R01AB06 OTRIVIN DUAL RELIEF B Xylometazoline HCl - 0.5mg/ml, Ipratropium bromide - 0.6mg/ml Solution 563,070 L.L
C09CA09 EDARBI B Azilsartan medoxomil - 40mg 40mg Tablet 1,846,440 L.L
C10AB05 LIPANTHYL B Fenofibrate - 160mg 160mg Tablet, film coated, modified release 1,154,238 L.L
J01DC04 CECLOR B Cefaclor (monohydrate) - 125mg/5ml 125mg/5ml Granules for suspension 487,623 L.L
J07BX05 ABRYSVO B RSV subgroup A stabilized perfusion F antigen 60mcg - 60mcg, RSV subgroup B stabilized perfusion F antigen 60mcg - 60mcg, Glycoprotein F stabilized in the perfusion conformation - Injectable powder + solvent 22,650,721 L.L
M01AE01 BRUFEN B Ibuprofen - 600mg 600mg Tablet, film coated 423,121 L.L
N03AX14 KEPPRA B Levetiracetam - 500mg 500mg Tablet, film coated 6,478,288 L.L
R01AB08 RINOFLUIMUCIL B Acetylcysteine - 1%, Tuaminoheptane sulfate - 0.5%, Benzalkonium chloride - 0.0125% Solution 419,279 L.L
R06AE07 ZYRTEC B Cetirizine (dihydrochloride) - 5mg/5ml Solution 278,175 L.L
B03AE10 TOT'HEMA B Copper (gluconate) - 0.70mg/10ml, Manganese (gluconate) - 1.33mg/10ml, Iron (gluconate) - 50mg/10ml Solution 604,729 L.L
C09CA09 EDARBI B Azilsartan medoxomil - 80mg 80mg Tablet 2,023,827 L.L
J07CA LANTIGEN B B Streptococcus pneumoniae type 3 (antigenic extracts) - 63.2A.U./ml, Streptococcus pyogenes group A (antigenic extracts) - 126.2A.U./ml, Branhamella catarrhalis (antigenic extracts) - 39.9A.U./ml, Staphylococcus aureus (antigenic extracts) - 79.6A.U./ml, Haemophilus influenzae type b (antigenic extracts) - 50.2A.U./ml, Klebsiella pneumoniae (antigenic extracts) - 39.8A.U./ml Drops suspension 916,501 L.L
L01EJ01 JAKAVI B Ruxolitinib - 15mg 15mg Tablet 341,075,567 L.L
    ...
    22
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025